Immutep Ltd Adr Stock Fundamentals
| IMMP Stock | USD 1.78 0.03 1.71% |
Immutep Ltd ADR fundamentals help investors to digest information that contributes to Immutep's financial success or failures. It also enables traders to predict the movement of Immutep Stock. The fundamental analysis module provides a way to measure Immutep's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Immutep stock.
Immutep |
Immutep Ltd ADR Company Operating Margin Analysis
Immutep's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Immutep Operating Margin | (8.39) % |
Most of Immutep's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immutep Ltd ADR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, Immutep Ltd ADR has an Operating Margin of -8.3924%. This is 76.08% lower than that of the Biotechnology sector and 92.51% lower than that of the Health Care industry. The operating margin for all United States stocks is 52.31% higher than that of the company.
Immutep Ltd ADR Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Immutep's current stock value. Our valuation model uses many indicators to compare Immutep value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Immutep competition to find correlations between indicators driving Immutep's intrinsic value. More Info.Immutep Ltd ADR is rated second overall in return on equity category among its peers. It is currently regarded as number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Immutep by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Did you try this?
Run Fundamentals Comparison Now
Fundamentals ComparisonCompare fundamentals across multiple equities to find investing opportunities |
| All Next | Launch Module |
Immutep Fundamentals
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.2 | ||||
| Operating Margin | (8.39) % | ||||
| Current Valuation | 161.94 M | ||||
| Shares Outstanding | 145.56 M | ||||
| Shares Owned By Insiders | 0.01 % | ||||
| Shares Owned By Institutions | 4.76 % | ||||
| Number Of Shares Shorted | 5.09 M | ||||
| Price To Earning | (152.55) X | ||||
| Price To Book | 2.35 X | ||||
| Price To Sales | 53.16 X | ||||
| Revenue | 3.84 M | ||||
| Gross Profit | (41.56 M) | ||||
| EBITDA | (44.54 M) | ||||
| Net Income | (42.72 M) | ||||
| Cash And Equivalents | 80 M | ||||
| Cash Per Share | 0.92 X | ||||
| Total Debt | 1.59 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 14.16 X | ||||
| Book Value Per Share | 0.12 X | ||||
| Cash Flow From Operations | (34.82 M) | ||||
| Short Ratio | 69.58 X | ||||
| Earnings Per Share | (0.21) X | ||||
| Target Price | 9.5 | ||||
| Beta | 1.98 | ||||
| Market Capitalization | 259.37 M | ||||
| Total Asset | 201.58 M | ||||
| Retained Earnings | (382.65 M) | ||||
| Working Capital | 180.86 M | ||||
| Current Asset | 1.89 M | ||||
| Current Liabilities | 1.04 M | ||||
| Net Asset | 201.58 M |
About Immutep Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Immutep Ltd ADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immutep using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immutep Ltd ADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical products. Immutep Limited was incorporated in 1987 and is headquartered in Sydney, Australia. Immutep operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.
Additional Tools for Immutep Stock Analysis
When running Immutep's price analysis, check to measure Immutep's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immutep is operating at the current time. Most of Immutep's value examination focuses on studying past and present price action to predict the probability of Immutep's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immutep's price. Additionally, you may evaluate how the addition of Immutep to your portfolios can decrease your overall portfolio volatility.